An Effort to Build a Better DMD Gene Therapy

Curran Simpson, CEO of Regenxbio, discusses the company’s platform technology, the advantages he sees with its experimental DMD gene therapy, and how a partnership announced at the start of 2025 focused on a pair of other gene therapies provided a welcome alternative to tapping the capital markets.